Safety and Tolerability of RGB-286638 in Patients With Selected, Relapsed or Refractory Hematological Malignancies
Status:
Withdrawn
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the safety and tolerability of RGB-286638, a novel,
multi-targeted kinase inhibitor, administered to patients with selected, relapsed or
refractory hematological malignancies.